Radiomics

Executive Summary

Radiomics is a Belgium-based AI-powered medical imaging and advanced statistics clinical research organization (CRO) specializing in oncology. Founded in 2019, the company extracts quantitative data from medical images to optimize the development of new cancer treatments. Its proprietary platform supports biotech and pharma companies across all stages of clinical development, aiming to improve drug response prediction and patient stratification. With the growing adoption of AI in medical imaging and the increasing emphasis on precision medicine, Radiomics is well-positioned to provide valuable imaging biomarkers that accelerate clinical trials. However, as a private, early-stage company with no disclosed funding, it faces challenges in scalability and market penetration. The increasing demand for quantitative imaging endpoints in oncology trials presents a significant opportunity for Radiomics to establish itself as a key partner. Its expertise in radiomics and focus on a niche but rapidly expanding field could attract strategic partnerships or investments, driving growth and validation.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a top pharmaceutical company for Phase III oncology trial using Radiomics platform40% success
• Q3 2026Series A funding round to scale platform and expand commercial operations50% success
• Q1 2027Publication of a peer-reviewed validation study demonstrating improved drug response prediction using AI-based imaging biomarkers60% success